Company intelligence / Profile preview

Ubique Beta Glucan

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Ubique is a biotechnology company focused on developing innovative health solutions using proprietary beta-glucan technology. The company specializes in the extraction and formulation of high-purity beta-glucans to enhance immune system response and serve as delivery vehicles for various therapeutic agents. Their research primarily targets infectious diseases and oncology, leveraging the natural immunomodulatory properties of yeast-derived compounds. Ubique aims to bridge the gap between nutritional supplements and pharmaceutical-grade therapeutics through rigorous clinical validation.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: BiologicProteinVaccine
Industry: Biotech

Beyond the preview

Go deeper on Ubique Beta Glucan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubique Beta Glucan.

Explore the full profile